A Long-term, Follow-up of the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Novel HPV Vaccine in Healthy Female Subjects Vaccinated in the Primary Study [EXTENSION of 700009996]

Trial Profile

A Long-term, Follow-up of the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Novel HPV Vaccine in Healthy Female Subjects Vaccinated in the Primary Study [EXTENSION of 700009996]

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Feb 2015

At a glance

  • Drugs GSK 568893A (Primary) ; AS04A; Human papillomavirus vaccine recombinant bivalent Japan Vaccine/MedImmune
  • Indications Cervical cancer; Cervical intraepithelial neoplasia; Human papillomavirus infections
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 04 Oct 2011 Actual end date of the extension trial (NCT00359619) is Aug 2009.
    • 04 Oct 2011 Actual end date of the extension trial (NCT00359619) is Aug 2009.
    • 04 Oct 2011 Actual end date of the extension trial (NCT00359619) is Aug 2009.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top